Novo Nordisk Advances Oral Semaglutide and CagriSema
Novo Nordisk starts a commercial and clinical comeback. Over the last two years, the company’s market worth has significantly decreased. This work is now anchored by recent phase 3 data for oral semaglutide. This strategic impetus is further reinforced by national regulatory submissions for CagriSema.
Over the previous month, stock prices have increased by about 17%. Values are still about 12% lower than the start of the year. Given this, the business strives for ambitious clinical goals. Restoring long-term investor confidence is the goal of these efforts.
Researchers presented OASIS 4 trial results at a major medical congress. Patients achieved an average weight loss of 21.6% over one year. Along with this, participants reported significant improvements in physical function. This oral tablet demonstrated high tolerability during the study period.
Compared to rival oral therapies, discontinuation rates continued to be significantly lower. In particular, fewer gastrointestinal adverse effects were reported by the patients. As a result, the oral formulation offers a practical substitute for injectable treatments. The growing importance of oral metabolic therapy is supported by this evidence.
In trade, the oral pill is still commonly utilized. Nearly a million individuals have begun this medication since January. In particular, this medication accounts for 65% of new category prescriptions. This volume demonstrates the strong preference for non-invasive delivery methods.
The weekly injectable category still holds over 55% of the market. Other manufacturers are making a stronger effort to compete. To elaborate, the original recipe is still very popular. The company manages these shifting market conditions with success.
Financial statistics for the first quarter show that the economy is stabilizing. Revenue reported increased by 32% to almost $14 billion. This rise came after multibillion-dollar provisions were made public. As a result, there are indications of underlying strength in the core business.
During this particular time frame, adjusted revenue decreased by 10%. Following these changes, earnings per share decreased by 3%. However, the obesity sector saw currency-adjusted increase of 22%. The management then reduced the financial guidance for the entire year. The most significant short-term catalyst is CagriSema.
An amylin analog and a GLP-1 agonist are combined in this weekly injectable. Given this, the REDEFINE 1 trial produced better findings. The mean weight loss from the combined therapy was 22.7%.
Monotherapy achieved only 16.1% weight loss in the same study. The company submitted this treatment for national regulatory approval. Officials anticipate a final decision by late 2026. Meanwhile, a large cardiovascular outcomes trial continues its enrollment phase.
Regarding the near-term trajectory, analyst opinions are still mixed. The stock is considered a top investment option by several firms. They state that there are 50 million addressable patients in the country. Despite successful product introductions, some institutions continue to retain a neutral rating.
The business just finished a sizable tranche of share repurchases. This is a component of a larger capital return initiative. Additionally, the price of shares is 13.6 times anticipated earnings. In comparison to the larger healthcare industry, this is a discount.
Over 900 million people worldwide suffer from obesity. Currently, less than 1% of patients receive branded medication. In light of this, there is still a lot of room for market growth. New patient care standards are still being driven by innovation.
A crucial test will be the impending regulatory ruling. It assesses whether recent successes are indicative of long-term commercial momentum. As a result, the business prioritizes clinical performance and scale. An urgent global health issue is the focus of these initiatives.
